Analysis of BC samples using the TCGA database highlighted the role of collagen type VI alpha 1 (COL6A1) as a hub gene, the expression of which was confirmed by immunohistochemical analysis of BC tissues and correlated with poor survival and response to anti-PD1 therapy [79]. This evidence concerns the gene COL6A1 and breast cancer.